Fierce Pharma Asia—Takeda’s GammaDelta buy, FDA warning letter removal; Fujifilm’s massive North Carolina plantnews2021-10-29T10:16:25+00:00October 29th, 2021|Fierce Pharma|
Merck’s big earnings in Q3 play second fiddle to enthusiasm for COVID pill’s potentialnews2021-10-28T15:15:57+00:00October 28th, 2021|Fierce Pharma|
Alnylam founding CEO Maraganore steps down after pioneering RNA interference therapynews2021-10-28T14:42:07+00:00October 28th, 2021|Fierce Pharma|
Up to 50M J&J COVID doses sit idle at Emergent plant, awaiting FDA inspection: reportnews2021-10-28T13:29:55+00:00October 28th, 2021|Fierce Pharma|
Takeda’s Japan plant reemerges from FDA warning letter as pharma works through pipeline setbacksnews2021-10-28T13:02:00+00:00October 28th, 2021|Fierce Pharma|
Sanofi’s €10B sales target for Dupixent? The ‘megabrand’ is more than halfway there, exec saysnews2021-10-28T12:43:36+00:00October 28th, 2021|Fierce Pharma|
Strides Pharma to pump $42M into former Endo manufacturing plant in New Yorknews2021-10-28T12:20:26+00:00October 28th, 2021|Fierce Pharma|
In midst of ADHD drug launch, Supernus taps ’90s sitcom actress for awareness campaignnews2021-10-27T20:46:07+00:00October 27th, 2021|Fierce Pharma|
With Revlimid erosion coming, Bristol Myers spotlights early performance of CAR-Ts Abecma, Breyanzinews2021-10-27T15:47:20+00:00October 27th, 2021|Fierce Pharma|
GlaxoSmithKline: Don’t count on a Shingrix rebound this year, but 2022 will bring ‘record sales’news2021-10-27T15:22:16+00:00October 27th, 2021|Fierce Pharma|
